Journal of Bone and Mineral Metabolism

, Volume 25, Issue 5, pp 302–309 | Cite as

Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate

  • Masayuki Kamatari
  • Shiro Koto
  • Nobuhiro Ozawa
  • Chie Urao
  • Yumiko Suzuki
  • Eri Akasaka
  • Kae Yanagimoto
  • Kazumi Sakota
ORIGINAL ARTICLE

Abstract

The aim of our study was to examine compliance with a daily dose of 5 mg alendronate (ALN) and 2.5 mg risedronate (RDN) in actual practice, and to determine the causes of noncompliance through a questionnaire. In addition, we studied the quality of life (QOL) of patients through another disease-related questionnaire. The overall compliance rate remained at approximately 40% one year after the initial dose. The rates did not differ significantly between the ALN group (783 patients) and the RDN group (491 patients). The compliances in the female group and the rheumatism group were better than in the male group and the nonrheumatism group. From the questionnaire, 36% of noncompliant patients showed adverse effects (AEs), and the other noncompliant patients stopped the medication in spite of having no AEs. A logistic regression analysis of factors that might have affected long-term compliance included AEs, an understanding of the disease, the method of ingestion, visiting medical facilities, the shape of the tablet, the cost of the drug, and the explanation of the doctor or pharmacist. This analysis showed that noncompliance occurred mainly due to AEs, the inconvenience of visiting a medical facility, unusual methods of ingestion, and a poor understanding of the disease. According to the results of the questionnaire for QOL assessment, the patients who continued the medication for more than 1 year had improved scores for pain in both the ALN and RDN groups. Osteoporotic treatment needs long-term patient compliance. To improve compliance, it is very important that doctors and pharmacists ensure that patients understand the purpose of this therapy.

Key words

compliance persistence osteoporosis bisphosphonate quality of life 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chapurlat, RD, Delmas, PD 2006Drug insight: bisphosphonates for postmenopausal osteoporosisNat Clin Pract Endocrinol Met2211219CrossRefGoogle Scholar
  2. 2.
    Kushida, K, Shiraki, M, Nakamura, T, Kishimoto, H, Morii, H, Yamamoto, K, Kaneda, K, Fukunaga, M, Inoue, T, Nakashima, M, Orimo, H 2004Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up studyJ Bone Miner Metab22462468PubMedCrossRefGoogle Scholar
  3. 3.
    Liberman, UA, Weiss, SR, Broll, J, Minne, HW, Quan, H, Bell, NH, Rodriguez-Portales, J, Downs, RW,Jr, Dequeker, J, Favus, M 1995Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosisN Eng J Med33314371443CrossRefGoogle Scholar
  4. 4.
    Black, DM, Cummings, SR, Karpt, DB, Cauley, JA, Tompson, DE, Nevitt, MC, Bauer, DC, Genant, HK, Haskell, WL, Marcus, R, Ott, SM, Torner, JC, Quandt, SA, Reiss, TF, Ensrud, KE 1996Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fracturesLancet34815351541PubMedCrossRefGoogle Scholar
  5. 5.
    Cummings, SR, Black, DM, Thompson, DE, Applegate, WB, Barrett-Connor, E, Musliner, TA, Palermo, L, Prineas, R, Rubin, SM, Scott, JC, Vogt, T, Wallace, R, Yates, AJ, LaCroix, AZ 1998Effect of alendronate on risk of fracture in women with low bone mineral density but without vertebral fracturesJAMA28020772082PubMedCrossRefGoogle Scholar
  6. 6.
    Ensrud, KE, Black, DM, Palermo, L, Bauer, DC, Barrett-Connor, E, Quandt, SA, Thompson, DE, Karpf, DB 1997Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention TrialArch Intern Med15726172624PubMedCrossRefGoogle Scholar
  7. 7.
    Harris, ST, Watts, NB, Genant, HK, McKeever, CD, Hangartner, T, Keller, M, Chesnut, CH,3rd, Brown, J, Eriksen, EF, Hoseyni, MS, Axelrod, DW, Miller, PD 1999Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosisJAMA28213441352PubMedCrossRefGoogle Scholar
  8. 8.
    Reginster, JY, Minne, HW, Sorensen, OH, Hooper, M, Roux, C, Brandi, ML, Lund, B, Ethgen, D, Pack, S, Rounagnac, I, Eastell, R 2000Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosisOsteoporos Int118391PubMedCrossRefGoogle Scholar
  9. 9.
    McClung, MR, Geusens, P, Miller, PD, Zippel, H, Bensen, WG, Roux, C, Adami, S, Fogelman, I, Diamond, T, Eastell, R, Meunier, PJ, Reginster, YJ 2001Effect of risedronate on the risk of hip fracture in elderly womanN Eng J Med344333340CrossRefGoogle Scholar
  10. 10.
    Macedo, JMS, Macedo, CRB, Elkis, H, Oliveira, IRD 1998Meta-analysis about the efficacy of anti-resorptive drugs in postmenopausal osteoporosisJ Clin Parm Ther23345352CrossRefGoogle Scholar
  11. 11.
    Cranney, A, Guyatt, G, Griffith, L, Wells, G, Tugwell, P, Rosen, C 2002Summary of meta-analyses of therapies for postmenopausal osteoporosisEndocr Rev23570576PubMedCrossRefGoogle Scholar
  12. 12.
    Andrade, SE, Walker, AM, Gottlieb, LK, Hollenberg, NK, Testa, MA, Saperia, GM, Platt, R 1995Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in a primary care setting?N Eng J Med33211251131CrossRefGoogle Scholar
  13. 13.
    McClung, B, McClung, M 2001Pharmacologic therapy for the treatment and prevention of osteoporosisNurs Clin North Am36433440PubMedGoogle Scholar
  14. 14.
    Tanaka, I, Hayakawa, K, Oshima, H 2003Tolerance of alendronate in patients with osteoporosis (in Japanese)Osteoporosis Japan11252255Google Scholar
  15. 15.
    Hamilton, B, McCoy, K, Taggart, H 2003Tolerability and compliance with risedronate in clinical practiceOsteoporos Int14259262PubMedGoogle Scholar
  16. 16.
    Yood, RA, Emani, S, Reed, JI, Lewis, BE, Charpentier, M, Lydick, E 2003Compliance with pharmacologic therapy for osteoporosisOsteoporos Int14965968PubMedCrossRefGoogle Scholar
  17. 17.
    Caro, JJ, Ishak, KJ, Huybrechts, KF, Raggio, G, Chistel, N 2004The impact of compliance with osteoporosis therapy on fracture rates in actual practiceOsteoporos Int1510031008PubMedCrossRefGoogle Scholar
  18. 18.
    Siris, ES, Harris, ST, Rosen, CJ, Barr, CE, Arvesen, JN, Abbott, TA, Silverman, S 2006Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databasesMayo Clin Proc8110091012CrossRefGoogle Scholar
  19. 19.
    Solomon, DH, Avorn, J, Katz, JN, Finkelstein, JS, Arnold, M, Polinski, JM, Brookhart, MA 2005Compliance with osteoporosis medicationsArch Intern Med16524142419PubMedCrossRefGoogle Scholar
  20. 20.
    Cramer, JA, Silverman, S 2006Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problemAm J Med119S1217PubMedCrossRefGoogle Scholar
  21. 21.
    Sambrook, P 2006Compliance with treatment in osteoporosis patientsAust Fam Physician35135137PubMedGoogle Scholar
  22. 22.
    Ettinger, MP, Gallagher, R, MacCosbe, PE 2006Medication persistence with weekly versus daily doses of orally administered bisphosphonatesEndocr Pract12522528PubMedGoogle Scholar
  23. 23.
    Lo, JC, Pressman, AR, Omar, MA, Ettinger, B 2006Persistence with weekly alendronate therapy among postmenopausal womenOsteoporos Int17922928PubMedCrossRefGoogle Scholar
  24. 24.
    Miyakoshi, N, Itoi, E, Kobayashi, M, Komada, H 2003Impact of postural deformities and spinal mobility on quality of life in postmenopausal osteoporosisOsteoporos Int1410071012PubMedCrossRefGoogle Scholar
  25. 25.
    Kushida, K, Fukunaga, M, Kishimoto, H, Shiraki, M, Itabashi, A, Inoue, T, Kaneda, K, Morii, H, Nawata, H, Yamamoto, K, Ohashi, Y, Orimo, H 2004A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trialJ Bone Miner Metab22469478PubMedGoogle Scholar
  26. 26.
    Romagnoli, E, Carnevale, V, Nofroni, I, D'Erasmo, E, Paglia, F, Geronimo, SD, Pepe, J, Raejntoph, N, Maranghi, M, Minisola, S 2004Quality of life in ambulatory postmenopausal women: the impact of reduced bone mineral density and subclinical vertebral fracturesOsteoporos Int15975980PubMedCrossRefGoogle Scholar
  27. 27.
    Yoh, K, Tanaka, K, Ishikawa, A, Ishibashi, T, Uchino, Y, Sato, Y, Tobinaga, M, Hasegawa, N, Kamae, S, Yoshizawa, M 2005Health-related quality of life (HRQOL) in Japanese osteoporotic patients and its improvement by elcatonin treatmentJ Bone Miner Metab23167173PubMedCrossRefGoogle Scholar
  28. 28.
    Tosteson, AN, Hammond, CS 2002Quality-of-life assessment in osteoporosis: health-status and preference-based measuresPharmacoeconomics20289303PubMedCrossRefGoogle Scholar
  29. 29.
    Takahashi, H, Iwaya, C, Iba, K, Gorai, I, Suzuki, T, Hayashi, Y, Hujinawa, S, Yamasaki, K, Endo, N 2001The Japanese Osteoporosis QOL Questionnaire (JOQOL): 2000 edition (in Japanese)J Jpn Soc Bone Miner Res1883100Google Scholar
  30. 30.
    Ohbayashi, H, Yamase, H 2004Efficacy of alendronate (Bonalon) in improving the quality of life of elderly Japanese patients with primary osteoporosisOsteoporosis Jpn12369376Google Scholar
  31. 31.
    Yamaoka, K, Tanigawara, T, Nakagawa, T, Uno, T 1981A pharmacokinetic analysis program (MULTI) for microcomputerJ Pharmacobio-dyn4879885PubMedGoogle Scholar
  32. 32.
    Aki, S, Eskiyurt, N, Akarirmak, U, Tuzun, F, Eryavuz, M, Alper, S, Arpacioglu, O, Atalay, F, Kavuncu, V, Kokino, S, Kuru, O, Nas, K, Ozerbil, O, Savas, G, Sendur, OF, Soy, D, Akyuz, G 2003Gastrointestinal side-effect profile due to the use of alendronate in the treatment of osteoporosisYonsei Med J44961967PubMedGoogle Scholar
  33. 33.
    Lanza, FL, Hunt, RH, Thomson, AB, Provenza, JM, Blank, MA 2000Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal womanGastroenterology119631638PubMedCrossRefGoogle Scholar
  34. 34.
    Segal, E, Tamir, A, Ish-Shalom, S 2003Compliance of osteoporotic patients with different treatment regimensIsr Med Assoc J5859862PubMedGoogle Scholar
  35. 35.
    Cramer, JA, Amonkar, MM, Hebborn, A, Altman, R 2005Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosisCurr Med Res Opin2114531460PubMedCrossRefGoogle Scholar
  36. 36.
    Gertz, BJ, Holland, SD, Kline, WF, Matuszewski, BK, Freeman, A, Quan, H, Lasseter, KC, Mucklow, JC, Porras, AG 1995Studies of the oral bioavailability of alendronateClin Pharmacol Ther58288298PubMedCrossRefGoogle Scholar
  37. 37.
    Mitchell, DY, Barr, WH, Eusebio, RA, Stevens, KA, Duke, FP, Russell, DA, Nesbitt, JD, Powell, JH, Thompson, GA 2001Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administrationPharm Res18166170PubMedCrossRefGoogle Scholar
  38. 38.
    Major, PP, Lipton, A, Berenson, J, Hortobagyi, G 2000Oral bisphosphonatesCancer88614PubMedCrossRefGoogle Scholar
  39. 39.
    Delmas, PD, Confavreux, E, Garnero, P, Confavreux, E, Garnero, P, Genolet, G, Gibelin, G, Yates, J 2001Can alendronate be taken before lunch or dinner? A randomized trial in osteoporotic womenJ Bone Miner Rest16S406Google Scholar
  40. 40.
    Mitchell, DY, Heise, MA, Pallone, KA, Clay, ME, Nesbitt, JD, Russell, DA, Melson, CM 1999The effect of dosing regimen on the pharmacokinetics of risedronateBr J Clin Pharmacol48536542PubMedCrossRefGoogle Scholar
  41. 41.
    Kamatari, M, Kataoka, N, Watanabe, Y, Tsuri, M, Fukuda, Y, Koto, S 2006Preference survey among osteoporotic patients with bisphosphonate treatment: once-daily and once-weekly dosing (in Japanese)Osteoporosis Jpn14765768Google Scholar
  42. 42.
    Simon, JA, Lewiecki, EM, Smith, ME, Petruschke, RA, Wang, L, Palmisano, JJ 2002Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover studyClin Ther2418711886PubMedCrossRefGoogle Scholar
  43. 43.
    Kendler, D, Kung, AWC, Fuleihan, GE, Gonzalez, JGG, Gaines, KA, Verbruggen, N, Melton, ME 2004Patients with osteoporosis prefer once weekly to once daily dosing with alendronateMaturitas48243251PubMedCrossRefGoogle Scholar
  44. 44.
    Ettinger, B, Black, DM, Mitlak, BH, Knickerbocker, RK, Nickelsen, T, Genant, HK, Christiansen, C, Delmas, PD, Zanchetta, JR, Stakkestad, J, Gluer, CC, Krueger, K, Cohen, FJ, Eckert, S, Ensrud, KE, Avioli, LV, Lips, P, Cummings, SR 1999Multiple outcomes of raloxifene evaluation (MORE) investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trialJAMA282637645PubMedCrossRefGoogle Scholar
  45. 45.
    Lufkin, EG, Wong, M, Deal, C 2001The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosisRheum Dis Clin N Am27163185CrossRefGoogle Scholar
  46. 46.
    Downey, TW, Foltz, SH, Boccuzzi, SJ, Omar, MA, Kahler, KH 2006Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care settingSouth Med J99570575PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 2007

Authors and Affiliations

  • Masayuki Kamatari
    • 1
    • 3
  • Shiro Koto
    • 2
  • Nobuhiro Ozawa
    • 2
  • Chie Urao
    • 1
  • Yumiko Suzuki
    • 1
  • Eri Akasaka
    • 1
  • Kae Yanagimoto
    • 1
  • Kazumi Sakota
    • 1
  1. 1.Maruzen PharmacyOsakaJapan
  2. 2.Koto OrthopedicInternal Medicine ClinicOsakaJapan
  3. 3.Kyoto Pharmaceutical UniversityKyotoJapan

Personalised recommendations